EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab–Bevacizumab

Hisanori Muto, Teiji Kuzuya, Yoshihiko Tachi, Yosuke Nagano, Yutaro Kajino, Misae Matsushita, Seiya Hagihara, Satoshi Yamamoto, Takashi Kobayashi, Yoshiaki Katano, Naoki Ohmiya, Senju Hashimoto und 11 weitere

Anticancer Research · 2026

DOI: 10.21873/anticanres.18056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Hisanori Muto und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan; hisanori.muto@fujita-hu.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Phenylurea Compounds, Liver Neoplasms, Quinolines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularPhenylurea CompoundsLiver NeoplasmsQuinolinesAntibodies, Monoclonal, HumanizedBevacizumabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesDisease ProgressionTreatment OutcomeAged, 80 and overAdultProgression-Free Survival

Stichwörter der Autor:innen

Atezolizumab plus bevacizumabearly progressionhepatocellular carcinomaimmune checkpoint inhibitorlenvatiniboverall survivalreal-world studysecond-line therapy

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, HumanizedatezolizumabBevacizumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan; hisanori.muto@fujita-hu.ac.jp.
  • Department of Gastroenterology and Hepatology, Fujita Health University Bantane Hospital, Nagoya, Japan.
  • Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan.
  • Department of Gastroenterology, Fujita Health University Okazaki Medical Center, Okazaki, Japan.
  • Department of Advanced Endoscopy, Fujita Health University, Toyoake, Japan.

Zitieren

APA

Muto, H., Kuzuya, T., Tachi, Y., Nagano, Y., Kajino, Y., Matsushita, M., Hagihara, S., Yamamoto, S., Kobayashi, T., Katano, Y., Ohmiya, N., Hashimoto, S., Ariga, M., Morisaki, S., Komura, G., Nakano, T., Tanaka, H., Nakaoka, K., Ohno, E., …, & Hirooka, Y. (2026). Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab–Bevacizumab. Anticancer Research. https://doi.org/10.21873/anticanres.18056

Vancouver

Muto H, Kuzuya T, Tachi Y, Nagano Y, Kajino Y, Matsushita M, et al. Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab–Bevacizumab. Anticancer Research. 2026. doi:10.21873/anticanres.18056

BibTeX
@article{Muto2026,
  author = {Muto, Hisanori and Kuzuya, Teiji and Tachi, Yoshihiko and Nagano, Yosuke and Kajino, Yutaro and Matsushita, Misae and Hagihara, Seiya and Yamamoto, Satoshi and Kobayashi, Takashi and Katano, Yoshiaki and Ohmiya, Naoki and Hashimoto, Senju and Ariga, Mizuki and Morisaki, Sayaka and Komura, Gakushi and Nakano, Takuji and Tanaka, Hiroyuki and Nakaoka, Kazunori and Ohno, Eizaburo and Funasaka, Kohei and Nagasaka, Mitsuo and Miyahara, Ryoji and Hirooka, Yoshiki},
  title = {Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab–Bevacizumab},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18056}
}
Kostenlos starten →